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Background.T h et h e ra pe u t i ce ﬃcacy of allogeneic hemopoietic stem cell transplantation (HSCT) largely relies on the graft-versus-
leukemia(GVL)eﬀect.Uncontrolledgraft-versus-hostdisease(GVHD)isafearedcomplicationofHSCT.RegulatoryTcells(Treg)
are a subset of CD4+ T-helper cells believed to maintain tolerance after HSCT. It remains unclear whether low peripheral blood
Treg have an impact on the risk for acute (aGVHD) and chronic GVHD (cGVHD). Methods. In this paper we enumerated the
CD4+CD25highCD127low Treg in the peripheral blood of 84 patients after at least 150 days from HSCT and in 20 healthy age-
matched controls. Results. Although similar mean lymphocyte counts were found in patients and controls, CD3+CD4+ T-cell
counts were signiﬁcantly lower in patients. Patients also had signiﬁcantly lower Treg percentages among lymphocytes as compared
to controls. Patients with cGVHD had even higher percentages of Treg if compared to patients without cGVHD. In multivariate
analysis, Treg percentages were not an independent factor for cGVHD. Conclusions. This paper did not show a relation between
deﬁcient peripheral blood Treg and cGVHD, therefore cGVHD does not seem to occur as a result of peripheral Treg paucity.
1.Introduction
Allogeneic hemopoietic stem cell transplantation (HSCT) is
a well-established treatment procedure with the potential to
cure a variety of hematological diseases. The graft-versus-
leukemia (GVL) eﬀect exerted by donor T cells can largely
contribute to its eﬃcacy, but the donor T-cell-mediated
graft-versus-host disease (GVHD) is a feared complication.
The challenge of allogeneic HSCT is to ﬁnd a balance
between beneﬁcial and harmful T-cell eﬀects. Naturally
arising regulatory T cells (Treg), a subset of CD4+ T-helper
cells expressing high levels of the interleukin-2 receptor α-
chain CD25 and the transcription factor forkhead box P3
(FoxP3) [1], have the ability to suppress aberrant immune
responses, to regulate peripheral T-cell homeostasis, and to
maintain self-tolerance [2–4]. Treg are believed to maintain
tolerance after solid organ transplantation and after HSCT
[5]. Studies using murine transplantation models showed
that allogeneic Treg promote engraftment, allow long-term
tolerance, and decrease incidence and severity of GVHD
without abrogating the beneﬁcial GVL eﬀect [6–13]. Human
studies investigating the impact of Treg on complications
after HSCT have so far generated rather conﬂicting results.
Generally CD4+CD25high T cells, which coexpress
FoxP3 are accepted as Treg [1, 3, 4]; however, FoxP3 is an
intracellular marker. Studies of Treg were hampered by the
lack of a suitable cell-surface marker apart from CD25, until
Liu et al. demonstrated that the downregulation of the α-
chain of the interleukin-7 receptor (CD127) on the majority
of the FoxP3 positive CD4+ T cells distinguishes Treg from2 The Scientiﬁc World Journal
activated T cells [14]. As CD127 is a cell surface marker, the
CD4+CD25highCD127low phenotype allows for consistent
identiﬁcation of human Treg in quantitative studies as well
as for enrichment of live Treg for functional analyses or
expansion in vitro [14, 15]. As determined by functional
assays, CD4+CD25highCD127low Treg show a suppressive
eﬀect in mixed lymphocyte culture studies [16, 17].
Several human studies have investigated the impact
of Treg on the complications after HSCT. Zorn et al.
found lower frequencies of CD4+CD25high Treg in the
peripheral blood of patients suﬀering from chronic GVHD
(cGVHD) compared to patients without cGVHD and to
healthy individuals; however, without diﬀerences in func-
tional studies [24]. Nadal et al. found higher frequencies
of CD4+CD25high Treg in the peripheral blood of patients
with chronic myeloid leukemia (CML) more than 18 months
after allogeneic HSCT compared to normal controls and to
newly diagnosed CML patients [18]. The study did not ﬁnd
ad i ﬀerence in Treg levels between patients with or without
cGVHD; however, patients with high Treg levels showed
evidence of disease relapse, thus an inhibition of the GVL
eﬀect by Treg was suggested [18]. CD4+CD25highFOXP3+
Treg were postulated to have a diagnostic and prognostic
value as a biomarker for acute GVHD (aGVHD) [19]. Ukena
et al. analyzed the recovery of CD4+CD25highCD127low
Treg after HSCT and found that numerically deﬁcient Treg
were associated with the development of aGVHD but not
cGVHD [20].
2.Objective
Until now the mechanisms of Treg recovery and their
suppressive activity in individuals after allogeneic HSCT are
not well understood. In this study we performed a cross-
sectional analysis of the lymphocyte subpopulations and
particularly of the CD4+CD25highCD127low Treg in the
peripheral blood in 84 patients after at least 150days from
allogeneic HSCT and in 20 healthy age-matched controls.
The aim of the study was to investigate the immunore-
constitution, especially the Treg reconstitution after HSCT,
to ﬁnd factors inﬂuencing Treg recovery and to assess the
impact of peripheral blood Treg on the development of
cGVHD.
3.MaterialandMethods
3.1. Subjects. Peripheral blood samples were routinely col-
lected after written informed consent was obtained in
accordance with the Declaration of Helsinki of 1975, as
revised in 2000, from 84 consecutive patients, who had
undergone allogeneic HSCT for hematological diseases at
the University Hospital in Heidelberg and from 20 healthy
controls. The local ethics committee at the University of
Heidelberg had approved sample collection. The median
age of controls (12 female, 8 male) was 42 years (25–62),
similarly the median age of patients (50 male, 34 female) was
46 years (19–67).
3.2. Stem Cell Transplantation Procedure. Details on trans-
plantation procedure and donor matching are summarized
in Table 1. Patients undergoing unrelated donor transplan-
tation received in vivo T-cell depletion with antithymocyte
globulin (ATG Fresenius) at total dose of 30–60mg/kg.
Patients with standard conditioning before HSCT received
cyclosporine A and short course of methotrexate on days +1,
+3, and +6 whereas patients with reduced intensity condi-
tioning (RIC) received cyclosporine A and mycophenolate
mofetil for GVHD prophylaxis. At the time of investigation,
the median time from transplantation was 533days (range
150–3606 days) and all patients attended the outpatient unit.
Patients were subdivided in three cohorts depending on the
time-point of investigation after HSCT: patients in cohort
1( n = 26) had the assessment within the timeframe of
150–360 (median 244) days after HSCT, patients in cohort
2( n = 22) within the timeframe of 360–720 (median 510)
daysafterHSCT,andpatientsincohort3(n = 36)aftermore
than 720 (median 1182, range 737–3606) days after HSCT.
This cohort analysis was performed in order to approximate
the immunoreconstitution at the diﬀerent time periods from
HSCT.
At the time of the study 31 patients (37%) were on
immunosuppressive treatment or had stopped immunosup-
pressives less than 2weeks prior to the study (9 cyclosporin
A, 2 tacrolimus, 5 mycophenolate mofetil, 3 steroids, 7
combination of calcineurin inhibitors with steroids, and 5
combination of calcineurin inhibitors with mycophenolate
mofetil). Molecular chimerism studies using short tandem
repeats (STR) ampliﬁcation of nine loci performed on the
mononuclear cell fraction in the bone marrow showed at
least a >95% donor chimerism in all 84 patients. AGVHD
and cGVHD were assessed and graded according to standard
criteria [21, 22]. At the time of the study 38 patients did
not have clinical signs of cGVHD whereas 46 patients (55%)
presented signs of cGVHD and 27 patients (32% of all)
suﬀered from extensive cGVHD.
3.3. Flow Cytometry
3.3.1. CD3+CD4+CD25highCD127low Treg Staining. The
enumeration of the lymphocyte subpopulations including
the CD4+CD25highCD127low Treg was performed by ﬂow
cytometry from fresh peripheral blood samples in ethylene-
diaminetetraaceticacid(EDTA).Abloodcountwasobtained
from each sample and subsequently a staining with appro-
priate combinations of the following monoclonal antibodies:
ﬂuorescein isothiocyanate- (FITC-) conjugated anti-CD25
(Beckman Coulter, Krefeld, Germany) and anti-CD8 (Bec-
ton Dickinson (BD) Pharmingen, Heidelberg Germany);
phycoerythrin- (PE-) conjugated anti-CD127 (BD Pharmin-
gen) and anti-CD19 (BD); peridiumchlorophyllprotein-
indopentamethicynine PerCP-Cy5.5-conjugated anti-CD4
(BD); allophycocyanin- (APC-) conjugated anti-CD56 (BD);
phycoerythrin-cyanine- (PE-Cy7-) conjugated CD3 (Caltag
L a b o r a t o r i e s ,B o t o l p hC l a y d o n ,U K )a sw e l la sI g Gi s o t y p e
controls. Brieﬂy, 100μl of undiluted sample containing
between 0.5–1 × 106 nucleated cells were incubated with
a combination of monoclonal antibodies for 15 minutes inThe Scientiﬁc World Journal 3
Table 1: Patient characteristics and transplantation details.
Patients (n = 84)
Age in years (median (range)) 46 (19–67)
Gender: male/female 50/34
Diagnosis:
AML/ALL/MDS 24/11/9
CML/OMF 7/3
CLL/NHL/MM 5/16/6
AA 3
Pretransplant conditioning:
Myeloablative regimens: 46
12 Gy TBI-cyclophosphamide/12 Gy TBI-etoposide 13/3
Busulphan-cyclophosphamide 8
8 Gy TBI-ﬂudarabine/melphalan-ﬂudarabine 4/16
Other 2
RIC regimens: 38
Fludarabine-cyclophosphamide/ﬂudarabine-busulphan/ﬂudarabine-cyclophosphamide-busulphan 9/3/7
2 Gy-ﬂudarabine 13
Other 6
Donor type: sibling/unrelated 38/46
Stem cell source: bone marrow/peripheral stem cells 2/82
HLA matching (10 antigens): match/mismatch 60/24
CMV serostatus of recipient and donor: both negative/other 22/62
Gender match: match/mismatch 45/39
Blood group match: match/mismatch 47/37
Time after transplantation in months (median (range)) 18 (5–120)
CML:chronicmyeloid leukaemia;AML: acute myeloidleukaemia;ALL: acute lymphoid leukaemia;NHL: non-Hodgkin’slymphoma; OMF: osteomyeloﬁbro-
sis; MM: multiple myeloma; CLL: chronic lymphatic leukaemia; MDS: myelodysplastic syndrome; AA: aplastic anaemia; RIC: reduced intensity conditioning;
CMV: cytomegalovirus; TBI: total body irradiation; HLA: human leucocyte antigen.
darkness at room temperature. 1mL of FACS wash and lyse
solution (Becton Dickinson BD) diluted 1:10 in distilled
water were added to each tube and after vortexing another
incubation for 15minutes in darkness at room temperature
was performed.
Cells were then centrifuged (5minutes at 1300U/min).
The last two steps were repeated and the labeled cells were
ﬁnally resuspended in 0.5mL/tube of phosphate buﬀered
saline. Antigen expression was analysed on an FACS Canto
ﬂow cytometer (Becton Dickinson, San Jose, CA, USA).
Data acquisition was performed with at least 50000 cells
per sample using BD Diva software (Becton Dickinson).
Data were analysed with Inﬁnicyt 1.0 software (Cytognos,
Salamanca, Spain). Frequencies of T-cell subpopulations
were calculated as percentages of positive cells in the total
lymphocyte gate. Figure 1 shows the gating strategy used to
deﬁne the Treg population. Absolute cell numbers for the T-
cell subpopulations were calculated from the leukocyte and
lymphocyte counts given by the full blood count performed
on the same sample.
3.3.2. CD3+CD4+CD25highFoxP3+ Treg Staining. Samples
were incubated with surface antibodies ﬁrst, cells were then
ﬁxed and permeabilized using the Human FoxP3 Buﬀer
Set (BD Pharmingen) and incubated with PE-conjugated
anti-FoxP3 (clone 259D/C7, BD Pharmingen) following
the manufacturer’s staining procedure recommendations.
Data were acquired and analysed as described above. In 20
healthy controls a positive correlation was found between
the percentages of CD3+CD4+CD25highCD127low and
CD3+CD4+CD25highFoxP3+ lymphocytes (r = 0.89, P =
0.002).
3.4. Statistical Analysis. Data are presented as median and
range or depicted as Box-Whisker plots [23]. Clinical
characteristics that may inﬂuence variations in lymphocyte
subpopulations were compared using Mann-Whitney U
test for 2 groups or Kruskal-Wallis test for three or more
groups. Fisher’s exact test was used to compare categorical
variables in the groups of patients with and without cGVHD.
Correlation was calculated using a rank-based Spearman
test. A logistic regression model was applied to analyse the
inﬂuence of clinical transplant factors on Treg percentages
among lymphocytes and on their counts in peripheral blood.
Treg values were dichotomized using the median value
obtained in the investigated population as a cutoﬀ. A logistic
regression model was also applied to analyse the clinical
transplant factors and lymphocyte subpopulations between4 The Scientiﬁc World Journal
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Figure 1: Treg gating strategy. Representative bivariate dot plots illustrating gating strategy used to enumerate lymphocytes with the
CD3+CD4+CD25highCD127low phenotype (Treg) in the same blood sample. The settings showed here were used for the analysis of all
peripheral blood samples. Events corresponding to Treg are shown as black dots, events corresponding to other lymphocytes are shown as
gray dots in all bivariate dot plots. (a) Gate shows CD3+CD4+ events corresponding to T-helper lymphocytes; (b) CD25highCD127low
events corresponding to Treg are displayed in the gate; (c) bivariate dot plot illustrating the CD4+CD25high phenotype pattern of Treg; (d)
bivariate dot plot illustrating the CD4+CD127low phenotype pattern of Treg: (e) and (f) bivariate dot plots showing appropriate isotype
controls. CD: cluster of diﬀerentiation.
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Figure 2: Inverse correlation between T-eﬀector cells
and Treg. Percentages of CD3+CD8+ T-eﬀector cells and
CD4+CD25highCD127low Treg are inversely correlated (r =
−0.55, P<0.0001) as shown by the trend line. Dots correspond to
individual samples from 84 patients. CD: cluster of diﬀerentiation,
Treg, regulatory T cells.
patients with and without cGVHD. Data were analysed using
the statistical package StatView for Windows (SAS Institute,
Cary, NC, USA). All quoted P values are two sided, with
P<0.05 being considered statistically signiﬁcant.
4. Results
4.1. Lymphocyte Populations in Patients and Controls.
Median leukocyte and lymphocyte counts were similar in
patients and healthy controls: 6155 × 106/l (1200–14800)
versus 6900 × 106/l (4800–9800) and 1377 × 106/l (87–
3423.8) versus 1555.9 × 106/l (675.8–2290.8), respectively.
CD3+CD4+T-cellcountsweresigniﬁcantlylowerinpatients
as compared to controls: 307.5 × 106/l (32.9–1124.6) versus
808.8 × 106/l (411–1091.4; P<0.001). Percentages of
CD4+CD25highCD127low Treg among total lymphocytes
and absolute numbers of Treg were signiﬁcantly lower in
patients if compared to controls: 1.9% (0.08–9.5) versus
3.8% (3.4–5.9) and 21.2 × 106/l (1.6–114.7) versus 56.4 ×
106/l (39.8–101.4; both P<0.001). Remarkably, no diﬀer-
encewasfoundinpercentagesofTregamongCD3+CD4+T-
lymphocytes with 8.3% (0.72–23.1) in patients versus 8.0%
(5.6–11.9) in controls. On the other hand percentages of
CD3+CD8+ T-eﬀector lymphocytes were higher in patients
thanincontrols:38.9%(10.9–83.6)versus24.2%(14.4–40.1)
(P = 0.004) and inversely correlated with Treg percentages
(rs =− 0.55, P<0.0001) as shown in Figure 2.L y m p h o c y t e
counts, CD3+CD4+ T-cell counts, and Treg counts were
positively correlated with the day from HSCT (r = 0.25, P =
0.02 for lymphocytes, r = 0.5, P<0.0001 for CD3+CD4+TThe Scientiﬁc World Journal 5
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Figure 3: Lymphocyte subpopulations and Treg within diﬀerent time periods from HSCT. Box plots graphs of lymphocyte subpopulation
frequencies in the three patient cohorts and in normal controls. The grafts show the dispersion around the median. The line across each box
represents the median for patients in cohort 1 (n = 26, median time from HSCT 244 days), in cohort 2 (n = 22, median time from HSCT
510 days), in cohort 3 (n = 36, median time from HSCT 720 days), and for normal controls (n = 20). The bottom edge is the ﬁrst quartile
and the top edge is the third quartile, the error bars represent the dispersion within the 95% conﬁdence interval, the dots represent extreme
values. Diﬀerences between the groups were explored using the Mann-Whitney U-test. Signiﬁcant diﬀerences between the groups are shown
above (P<0.05). All other diﬀerences between the median values were not signiﬁcant (P>0.05). CD: cluster of diﬀerentiation.
cells and r = 0.29, P = 0.008 for Treg). Percentages of
CD19+ B-lymphocytes and CD3-CD56+ natural killer (NK)
cells were similar in patients and controls (16.1% (1.9–55.9)
versus 10.6% (8.3–16.4), 2.6% (0.4–18.2) versus 2.9% (1.2–
6.7), resp.).
4.2. Lymphocyte Populations in Cohorts of Patients Studied
at Diﬀerent Time Periods from HSCT. The total leukocyte
counts were similar in the cohorts 1, 2, and 3. Lymphocyte
and CD3+ T-cell counts were signiﬁcantly lower in cohort
1 than in the cohorts 2 and 3: 1107.7 × 106/l (161–2744)
lymphocytes and 739 × 106/l (92–2333) CD3+ T cells
(P = 0.05) in cohort 1, but 1348.5 × 106/l (118–3328)
lymphocytes and 1029 × 106/l (104–2812) CD3+ T cell
in cohort 2 and 1639.7 × 106/l (653–3416) lymphocytes
and 1082 × 106/l (512–2320) CD3+ T cells in cohort 3
(P<0.01 for lymphocytes and P = 0.05 for CD3+
T cells in cohort 1 if compared to cohort 2 and 3), see
Figure 3. CD3+CD4+ T-cell counts were signiﬁcantly lower
in cohort 1 with 149 × 106/l (33–802) than in cohort 2
with 312 × 106/l (46–624; P<0.001). Also, CD3+CD4+ T-
cell counts were signiﬁcantly lower in cohort 2 if compared
to cohort 3 (411 × 106/l (214–1124; P = 0.03)). The
percentages of CD4+CD25highCD127low Treg among total
lymphocytes were not diﬀerent in the three cohorts: 1.8%
(0.1–9.5)incohort1versus1.6%(0.1–4.2)incohort2versus
2.1% (0.7–4.9) in cohort 3 but signiﬁcantly lower than in
controls (3.8% (3.4–5.9; P<0.001)). The percentages of
CD4+CD25highCD127low Treg among CD3+CD4+ T cells
were not diﬀerent in the three cohorts: 8.2% (2–18.3) in
cohort1versus8.0%(0.9–20.5)incohort2versus8.4%(1.3–
17) in cohort 3 and similar to those in controls (8% (5.6–
11.9; P<0.001)). In cohort 3 percentages of CD3+CD8+
T-eﬀector lymphocytes were lower (33%, 14–58) than in
the cohorts 1 (47%, 12–83.5) and 2 (49%, 18.5–72.5; P =
0.02). As demonstrated in Figure 3 lymphocyte counts reach
levelsofnormal controlsalreadywithinthe secondyearfrom
HSCT whereas the proportions of CD3+CD4+ T cells and
Treg among lymphocytes are lower than in controls even
after longer than two years from HSCT.
4.3. Analysis of Factors for Treg Expansion after HSCT. The
univariate analysis of factors that could potentially impact
on Treg reconstitution included the factors: patient age,
type of transplant conditioning, donor type (sibling versus
unrelated), HLA match, gender match, the use of in vivo T-
celldepletionwithATG,CMVserology(negativeinrecipient
and donor versus others), ongoing immunosuppression, and
previous acute GVHD and was ﬁrst performed separately in
the three patients cohorts (cohort 1, 2, and 3 as described
before) and in the second step in the whole group of n = 84
patients.
TheanalysisshowedanimpactofnegativeCMVserology
of donor and recipient (P = 0.045) on Treg percentages
in cohort 2 and an impact of ongoing immunosuppression
(P = 0.005 for Treg percentages and P = 0.02 for Treg
counts) in cohort 3 (n = 36). The analysis in the whole
group of n = 84 patients showed a signiﬁcant correlation
between the time from HSCT and Treg counts (P = 0.008)
and signiﬁcantly higher Treg percentages in patients with6 The Scientiﬁc World Journal
Table 2: Univariate analysis of factors with impact on the CD4+CD25highCD127low Treg frequencies and counts in 84 patients after
allogeneic HSCT.
CD4+CD25highCD127low P value CD4+CD25highCD127low P value
%o fl y m p h o c y t e s ×106/l
n = 84
Time of the Treg investigation from
HSCT (days)
0.56 0.008
Median Median
Patient age:
<45 years n = 36 1.87 0.47 20.95 0.94
>45 years n = 48 2.0 23.1
Donor type:
Sibling n = 38 2.14 0.075 24.0 0.17
Unrelated n = 46 1.8 19.8
Transplant conditioning:
Myeloablative n = 46 1.83 0.24 21.75 0.51
RIC n = 38 2.26 20.84
In vivo T-cell depletion (ATG):
No ATG n = 30 2.14 0.33 25.65 0.03
Use of ATG n = 54 1.81 19.15
HLA matching:
Matched n = 60 1.93 0.63 24.5 0.12
Mismatched n = 24 1.98 17.87
Gender matching:
Match n = 45 1.84 0.63 20.25 0.78
Mismatch n = 39 2.05 22.23
CMV serostatus:
Negative/negative n = 22 2.21 0.041 23.86 0.86
Other n = 62 1.81 20.84
History of acute GVHD:
None n = 51 2.05 0.44 19.13 0.74
Grade I–IV n = 33 1.91 23.5
Immunosuppression at time of study:
No n = 53 1.83 0.46 21.27 0.9
Yes n = 31 2.2 21.05
CD: cluster of diﬀerentiation; Treg: regulatory T cells; HSCT: haematopoietic stem cell transplantation; CMV: cytomegalovirus; GVHD: graft-versus-host
disease.
negative CMV serology in both patient and donor (P =
0.04). A trend was seen towards higher Treg percentages
in patients who received sibling HSCT (P = 0.075). The
analysis also found signiﬁcantly higher Treg counts in a
transplantsettingwithouttheuseofATG(P = 0.03).Seealso
Table 2. A logistic regression model using the cutoﬀ value of
1.93% for Treg percentages or the cutoﬀ value of 21.2×106/l
for Treg counts did not reveal an independent prognostic
parameter.
4.4. Treg Expansion in Patients with cGvHD and in Patients
without cGvHD. At the time of Treg investigation 46
patients (55%) had clinical signs of cGVHD. Patient with
or without cGVHD were not diﬀerent with respect to age,
gender, and transplantation procedure details like type of
conditioning, donor type, donor matching, cytomegalovirus
matching, gender matching, or blood group matching (see
Table 3). As shown in Figure 4 patients with cGVHD had
higher CD3+CD4+ T-cell percentages than patients without
cGVHD (P = 0.02). Treg percentages among total lympho-
cytes were higher in patients with cGVHD when compared
to patients without cGVHD (P = 0.03). Treg percentages
among CD3+CD4+ T lymphocytes were similar in both
patient groups: 8.2% (3.3–23.1) versus 8.5% (0.7–19.5) and
also no diﬀerences were found with respect to CD3+CD8+
T-eﬀector lymphocytes, CD19+ B cells, and CD3-CD56+
NK cells. In both groups Treg percentages were signiﬁcantly
lower if compared to healthy controls.
A logistic regression model for cGVHD including the
factors donor type and in vivo T-cell depletion with ATG
together with CD3+CD4+ T cells did not reveal an inde-
pendent factor. A similar logistic regression model including
the factors donor type and in vivo T-cell depletion with ATG
together with Treg percentages or Treg counts did not reveal
an independent factor for cGVHD.The Scientiﬁc World Journal 7
Table 3: Univariate analysis for chronic graft versus host disease (cGVHD).
No cGVHD (n = 38) Limited or extensive cGVHD (n = 46) P value
Median (range) Median (range)
Patient age (year) 44.5 (19–63) 46.5 (19–67) 0.17
Time after transplantation (day) 505 (150–2430) 577.5 (164–3606) 0.41
Lymphocytes × 106/l 1383 (99.5–3415.8) 1299 (118–3423.8) 0.68
CD3+CD4+ % of lymphocytes 33.2 (6.3–62.9) 22.6 (3.4–62.9) 0.02
CD3+CD4+ × 106/l 249.5 (34–1124.6) 312.4 (32.9–1094) 0.07
CD4+CD25highCD127low % of lymphocytes 1.7 (0.08–4.2) 2.2 (0.5–9.5) 0.026
CD4+CD25highCD127low × 106/l 17.06 (1.6–79.4) 24.5 (2.96–114.7) 0.033
Number Number
Gender (male/female) 24/14 26/20 0.65
Conditioning (myeloablative/RIC) 22/16 24/22 0.66
Donor type (sibling/unrelated) 14/24 24/22 0.19
In vivo T-cell depletion with ATG (no/yes) 10/28 20/26 0.11
HLA match (match/mismatch) 10/28 14/32 0.8
CMV serostatus (negative in both/other) 8/30 14/32 0.46
Gender match (match/mismatch) 22/16 23/23 0.51
Blood group match (match/mismatch) 20/18 28/18 0.5
CD:clusterofdiﬀerentiation,RIC:reducedintensityconditioning,ATG:antithymocyteglobulin,HLA:humanleukocyteantigen,andCMV:cytomegalovirus.
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Figure 4: Lymphocyte subpopulations and Treg in patients with cGVHD and in patients without cGVHD. Box plot graphs of lymphocyte
subpopulationfrequenciesinpatientsandhealthycontrols.ThegraphsshowthedispersionaroundthemedianforpatientswithoutcGVHD
(n = 38), for patients with cGVHD (n = 46), and for normal controls (n = 20). The line across each box represents the median, the bottom
edge the ﬁrst quartile, and the top edge the third quartile, the error bars represent the dispersion within the 95% conﬁdence interval and
the dots represent extreme values. Diﬀerences between the groups were explored using the Mann-Whitney U-test. Signiﬁcant diﬀerences
between the groups are shown above (P<0.05). All other diﬀerences between the median values were not signiﬁcant (P>0.05). CD: cluster
of diﬀerentiation, Treg: regulatory T cells, and cGVHD, chronic graft versus host disease.
5. Discussion
InthisstudyweenumeratedCD4+CD25highCD127lowTreg
in order to investigate their reconstitution after allogeneic
HSCT and their impact on cGVHD. Similar to the approach
used by Zorn et al. we chose to examine the frequency
of Treg over total lymphocytes; however, Zorn investigated
the CD4+CD25high Treg population whereas we assessed
the CD4+CD25highCD127low Treg subset [24]. In contrast,
Clark and Nadal investigated the CD4+CD25high Treg
population as percentage of CD4+ T-cells [18, 25]. We
and others believe, that other than absolute numbers, the8 The Scientiﬁc World Journal
frequency measurements reﬂect the ratio of Treg to the total
cells to be regulated and thus represent a more accurate
reﬂection of the Treg function in vivo [24]. Remarkably, the
diﬀerent ﬂow cytometry approaches (CD4+CD25high ver-
sus CD4+CD25highCD127low) and the diﬀerent frequency
measurements (Treg as a percentage of CD4+ T cells versus
Treg as a percentage of total lymphocytes) may generate
conﬂicting results.
FoxP3 is an intracellular marker and its investiga-
tion leads to time- and cost-consuming ﬂow cytometry
approaches. Liu et al. demonstrated that by the down
regulation of CD127 the FoxP3 positive Treg can be dis-
tinguished from activated T cells [14]. The enumeration
of the CD4+CD25highCD127low population has since
then been chosen to characterize Treg in human stud-
ies. Recently Ukena et al. used this approach in patients
after allogeneic HSCT [20]. In this study we were able
to show a highly signiﬁcant positive correlation between
the CD4+CD25highCD127low and the CD4+FoxP3+ Treg
populations in 20 healthy controls and decided to use
the CD4+CD25highCD127low Treg enumeration as a cost-
eﬀective ﬂow cytometry approach. We have not per-
formed functional tests; however, functional tests in pre-
vious studies have conﬁrmed the regulatory capacity of
CD4+CD25highCD127low Treg [14, 15]. In contrast to
murine studies relatively little is known on reconstitution of
T-cell subsets and the impact of Treg on complications after
allogeneic HSCT in humans. Rezvani et al. monitored Treg
during immune reconstitution in patients with leukemia
afterT-cell-depletedallogeneicHSCT[26].EarlyafterHSCT,
there was a signiﬁcant expansion in the CD4+FoxP3+
compartment, on the other hand a low CD4+FoxP3+ Treg
count early after HSCT was associated with an increased risk
of GVHD [26]. High numbers of CD4+FoxP3+ Treg within
the stem cell graft were shown to reduce the risk of aGVHD
in HLA matched allogeneic HSCT [26]. Treg content in the
graft also predicts the outcome of unrelated donor HSCT
[27].
In this cross-sectional study we documented an
insuﬃcient recovery of CD4+ T lymphocytes and
CD4+CD25highCD127low Treg in patients after at least 150
days from allogeneic HSCT if compared to healthy controls.
As expected lymphocyte counts and CD4+ T-cell counts
correlated with time from allogeneic HSCT. We showed
that also CD4+CD25highCD127low Treg counts correlated
with time from allogeneic HSCT. A longitudinal analysis has
not been performed in this study, but the cohort analysis
of patients at diﬀerent time-periods from allogeneic HSCT
demonstrates that CD4+ T-cell counts are lower than in
controls even after more than two years. Treg adequately
expand as a proportion of CD4 T-cells already within the
ﬁrst year from HSCT, CD4+ T-cells, however, remain lower
than in controls even after 2 years from HSCT and as a
consequence Treg counts and percentages among total
lymphocytes remain lower than in controls. An inverse
correlation was found between the percentages of Treg
among total lymphocytes and the percentages of T-eﬀector
lymphocytes indicating a physiologic interaction between
these two populations. These data conﬁrm the results
of previous studies showing that immune reconstitution
following allogeneic HSCT is characterizes by a rapid
expansion of peripheral CD3+CD8+ T-eﬀector cells and
delayed recovery of CD3+CD4+ T-cells [24, 28].
Theunivariateanalysisoffactorswithpotentialinﬂuence
on Treg reconstitution showed that patients with negative
CMV serology and CMV negative donors had signiﬁcantly
higherTregpercentages.Thisfactpossiblyreﬂectstheimpact
of CMV virus on reconstitution of CD4+ T-cells and
Treg after HSCT. The univariate analysis also showed that
patients after longer than 2 years from HSCT and ongoing
immunosuppression had lower Treg percentages. A trend
towards lower Treg percentages was seen in patients after
unrelated donor HSCT, after in vivo T-cell depletion with
ATG and in a HLA mismatched transplant setting. The
logistic regression analysis of these factors, however, did
not reveal an independent factor for Treg reconstitution.
This study showed that CD4+CD25highCD127low Treg
percentages among CD4+ T-cells are similar to those in
healthy controls already within the ﬁrst year after HSCT,
indicating that the recovery of Treg closely follows the CD4+
T-cell recovery.
CGVHD remains the most frequent complication of
allogeneic HSCT occurring in 30% to 70% of long-term
survivors and is characterized by a state of profound
immunodeﬁciency and defects in immunologic tolerance
[29]. The immune mechanisms leading to diverse clinical
manifestations of cGVHD remain largely unknown [30, 31].
Several studies in murine models have demonstrated the
critical role of Treg with respect to GVHD control [8–
10]. In humans, it remains unclear whether the impairment
in peripheral blood Treg after HSCT contributes to the
development of GVHD. In this study we found higher CD4+
T-cell and consequently higher CD4+CD25highCD127low
Treg counts and percentages in patients with cGVHD as
compared to patients without cGVHD, but in a logistic
regression model Treg counts or percentages were not an
independent factor for cGVHD. This cross-sectional analysis
of 84 patients after HSCT did not reveal a relation between
Treg counts in peripheral blood and the occurrence of
cGVHD. We therefore postulate that cGVHD does not occur
as a result of peripheral Treg paucity. Similar to this study,
Nadal et al. found no diﬀerences in CD4+CD25high Treg in
peripheral blood in patients with or without cGVHD [18].
Also Clark et al. found elevated percentages and absolute
numbers of CD4+CD25high T cells in patients with cGVHD
and concluded that cGVHD injury does not occur as a result
of Treg deﬁciency [25]. On the other hand, Zorn et al.
found decreased frequencies of circulating CD4+CD25high
Treg and lower FoxP3 expression by quantitative PCR in
patients with cGVHD [24]. Similarly to the results of this
study, Ukena et al. did not ﬁnd a relation between peripheral
CD4+CD25highCD127low Treg and cGVHD in a smaller
patient group [20]. This study conﬁrmed the results of
Ukena et al. using a similar ﬂow cytometry approach and
it generated similar results to those of Nadal et al. [18]
and Clark et al. [25], who both used diﬀerent cytometryThe Scientiﬁc World Journal 9
approaches. The study by Zorn et al. [24] remains to date
theonlyonewhichshowedanassociationbetweendecreased
Treg and cGVHD. To our knowledge this is the second
study that used the CD4+CD25highCD127low staining for
Treg enumeration in patients after allogeneic HSCT. This
method may be more cost- and time-eﬀective than the use
of intracellular techniques.
6. Conclusions
In this study we found a positive correlation between
CD3+CD4+ T-cell counts and CD4+CD25highCD127low
Treg counts and the time after allogeneic HSCT and showed
a rapid expansion of peripheral CD3+CD8+ T-eﬀector cells
and a delayed recovery of CD3+CD4+ T cells and Treg after
allogeneic HSCT. CD3+CD4+ T cells and Treg remain lower
thanincontrolsevenafter2yearsfromallogeneicHSCT.The
Treg recovery closely follows the CD3+CD4 T-cell recovery.
We did not ﬁnd an impact of peripheral Treg on cGVHD.
According to the speciﬁc site hypothesis cGVHD takes place
in peripheral tissues and therefore Treg and their possible
protective eﬀect on cGVHD have to be assessed in target
organs [32].
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